EMA — authorised 20 December 2013
- Application: EMEA/H/C/002546
- Marketing authorisation holder: Teva Pharma GmbH
- Local brand name: Nerventra
- Indication: Treatment of multiple sclerosis
- Status: rejected
🇪🇺 Nerventra in European Union
EMA authorised Nerventra on 20 December 2013
Marketing authorisation
Nerventra in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Nerventra approved in European Union?
Yes. EMA authorised it on 20 December 2013.
Who is the marketing authorisation holder for Nerventra in European Union?
Teva Pharma GmbH holds the EU marketing authorisation.